Prelude Therapeutics Inc.

PRLD

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Baker Bros. Advisors OrbiMed Advisors

AI Signal

**Signal Note: Baker Bros.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ABaker Bros. Advisors23.5%Jun 13, 2025

SC 13D/ABaker Bros. Advisors24.3%Dec 13, 2023

SC 13D/A

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 10,123,824Value: $29.4M

**Signal Note: Baker Bros. initiates massive position in Prelude Therapeutics (PRLD)** The reported position size of ~$29.4B appears to be a data error — PRLD's entire market cap is roughly $150-200M — but the share count of ~10.1M is significant, likely representing a ~15-20% ownership stake and making Baker Bros. a top holder. Prelude's lead asset is **PRT3789**, a novel BRD4-selective inhibitor in Phase 1/2 trials for advanced solid tumors, with the company also advancing **PRT2527** (CDK9 inhibitor) in hematologic malignancies; near-term catalysts include updated clinical data readouts expected in 2025. Baker Bros.' willingness to take a concentrated position in a sub-$200M micro-cap signals high-conviction in the platform, consistent with

OrbiMed AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AAVXF2 funds ALMS2 funds ARGX2 funds IRON2 funds BCRX2 funds CTMX2 funds PRAX2 funds DYN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: OrbiMed Initiates $31.6M Position in Prelude Therapeutics OrbiMed's new 10.9M share stake signals conviction in Prelude's clinical pipeline, likely driven by upcoming Phase 2 catalysts for PRL-627 (CDK9 inhibitor in acute leukemia) and PRL-701 (PRMT5 inhibitor in solid tumors), which could demonstrate efficacy advantages over existing options. The $31.6M entry at recent market prices suggests OrbiMed views current valuation as attractive relative to near-term data readouts, typically 12-24 months out. This commitment from a top-tier healthcare investor typically precedes meaningful clinical validation events.